Merck & Co., Inc.
MRK · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -7.98 | 1.75 | 0.17 |
| FCF Yield | 7.18% | 3.22% | 5.24% | 4.98% |
| EV / EBITDA | 10.77 | 45.41 | 14.08 | 12.32 |
| Quality | ||||
| ROIC | 18.97% | 0.71% | 18.53% | 13.90% |
| Gross Margin | 76.32% | 73.17% | 70.63% | 72.02% |
| Cash Conversion Ratio | 1.25 | 35.63 | 1.31 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.67% | 7.27% | 12.61% | 7.58% |
| Free Cash Flow Growth | 97.92% | -37.83% | 52.23% | 73.48% |
| Safety | ||||
| Net Debt / EBITDA | 0.97 | 4.26 | 0.91 | 1.48 |
| Interest Coverage | 15.91 | 2.58 | 19.00 | 16.38 |
| Efficiency | ||||
| Inventory Turnover | 2.49 | 2.54 | 2.95 | 2.29 |
| Cash Conversion Cycle | 107.23 | 117.97 | 92.71 | 105.17 |